Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-12-19

FDA Approved: BILTRICIDE — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for Biltricide (praziquantel) to update the label with expanded indications for treating helminth infections, including …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BILTRICIDE (praziquantel)

Snippet

SUPPL AP for BILTRICIDE (PRAZIQUANTEL)